Royalty Report: Drugs, Therapeutic, Disease – Collection: 233496

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 18

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 18

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Diagnostic
  • Antibody
  • Cancer
  • Drug Discovery
  • Immune
  • Genome
  • Surgical
  • Biotechnology
  • Molecular
  • HPV
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233496

License Grant
Pursuant to this agreement, the Licensee has the right to grant sub-licenses to Licensees product.  The Licensee may grant a Sublicense with respect to any Licensee Product for use in the Therapeutic Field, and, the Diagnostic Field.

During the Research term of this agreement, Licensee shall not make any other grant to the related antigens.

License Property
Licensee Product shall mean, with respect to any Licensee Licensed Antigen, any product comprising an Antibody which binds to such Licensee Licensed Antigen, or Genetic Material that encodes such an Antibody wherein, in respect of each Licensee Product, said Genetic Material does not encode multiple antibodies.

Antigens shall mean, collectively, the Research Antigens, Eligible Antigens, Optioned Antigens and Licensed Antigens, and Antigen shall mean any one of the Antigens.

Research Antigens shall mean, collectively, the antigens which are selected by the Collaboration, Licensor or Licensee for use in the Research Program, for which Licensor and Licensee have the right to grant the other party the commercial license, and which are not Optioned Antigens or Licensed Antigens, and Research Antigen shall mean any one of the Research Antigens.

Field of Use
The Commercial Field shall mean, collectively, the Therapeutic Field and the Diagnostic Field.

The Diagnostic Field shall mean the use of Products for the following human medical purposes: the detection, diagnosis and monitoring of any disease, predisposition, state or condition in humans or the selection of a particular patient(s) to receive a particular therapeutic treatment(s).

The Therapeutic Field shall mean the use of Products for the following human medical purposes: the prevention or treatment of any disease, state or condition in humans.

The goal of the five-year alliance is to develop antibody therapeutics against promising antibody drug targets in the human genome. The candidates are intended to treat a broad range of diseases, including metabolic diseases, cancer, inflammation, and autoimmune disorders.

IPSCIO Record ID: 233831

License Grant
Pursuant to this agreement, Licensor may grant a Sublicense with respect to any Licensor Product for use in the Therapeutic Field or Diagnostic field.

During the Research term, Licensor shall not make any other grant to the related antigens.

License Property
Licensors Product shall mean, with respect to any Licensor Licensed Antigen, any product comprising an Antibody which binds to such Licensor Licensed Antigen; or Genetic Material that encodes such an Antibody wherein, in respect of each Licensor Product, said Genetic Material does not encode multiple antibodies.

Licensor Licensed Antigens shall mean all Licensor Optioned Antigens for which Licensor has exercised an option to obtain a commercial license, and Licensor Licensed Antigen shall mean any one of the Licensor Licensed Antigens.

Licensor Optioned Antigens shall mean all antigens which are selected from the Eligible Antigens by Licensor, for which Licensee has the right to grant Licensor the commercial license, and which are not Licensed Antigens, and Licensor Optioned Antigen shall mean any one of the Licensor Optioned Antigens.

Field of Use
The Commercial Field shall mean, collectively, the Therapeutic Field and the Diagnostic Field.

The Diagnostic Field shall mean the use of Products for the following human medical purposes: the detection, diagnosis and monitoring of any disease, predisposition, state or condition in humans or the selection of a particular patient(s) to receive a particular therapeutic treatment(s).

The Therapeutic Field shall mean the use of Products for the following human medical purposes: the prevention or treatment of any disease, state or condition in humans.

The expanded alliance agreement is to develop and commercialize up to 250 fully human antibody drug candidates across all disease areas.

The goal of the five-year alliance is to develop antibody therapeutics against promising antibody drug targets in the human genome. The candidates are intended to treat a broad range of diseases, including metabolic diseases, cancer, inflammation, and autoimmune disorders.

IPSCIO Record ID: 233830

License Grant
Pursuant to this agreement, Licensor may grant a Sublicense with respect to any Licensor Product for use in the Therapeutic Field or Diagnostic field.

During the Research term, Licensor shall not make any other grant to the related antigens.

License Property
Licensors Product shall mean, with respect to any Licensor Licensed Antigen, any product comprising an Antibody which binds to such Licensor Licensed Antigen; or Genetic Material that encodes such an Antibody wherein, in respect of each Licensor Product, said Genetic Material does not encode multiple antibodies.

Licensor Licensed Antigens shall mean all Licensor Optioned Antigens for which Licensor has exercised an option to obtain a commercial license, and Licensor Licensed Antigen shall mean any one of the Licensor Licensed Antigens.

Licensor Optioned Antigens shall mean all antigens which are selected from the Eligible Antigens by Licensor, for which Licensee has the right to grant Licensor the commercial license, and which are not Licensed Antigens, and Licensor Optioned Antigen shall mean any one of the Licensor Optioned Antigens.

Field of Use
The Commercial Field shall mean, collectively, the Therapeutic Field and the Diagnostic Field.

The Diagnostic Field shall mean the use of Products for the following human medical purposes: the detection, diagnosis and monitoring of any disease, predisposition, state or condition in humans or the selection of a particular patient(s) to receive a particular therapeutic treatment(s).

The Therapeutic Field shall mean the use of Products for the following human medical purposes: the prevention or treatment of any disease, state or condition in humans.

The Companies said they hope to develop antibody therapies to treat metabolic diseases, cancer, inflammation and autoimmune disorders.

IPSCIO Record ID: 227238

License Grant
Research License; Supply of Mice; Materials ownership:
Licensor hereby grants to Licensee, a Japanese corporation, and the Majority-Owned Affiliates of Licensee, solely as needed to exercise the rights that may be granted, a paid-up, non-exclusive license and/or sublicense of its rights, as the case may be, under the Licensed Technology, without the right to grant further sublicenses, to (i) Breed the XenoMouse Animals included solely for use in the Research Field in connection with activities described in subsections (ii) and (iii) of this Section 2.1.1, (ii) immunize such XenoMouse Animals solely with those Antigens that are Permitted Antigens at the time of immunization and (iii) use the Research Program Materials and Information solely for conducting research and development work within the scope of the Research Field.

Licensor hereby grants to Licensee, and the Majority-Owned Affiliates of Licensee solely as needed to practice the rights that may be granted in accordance with this agreement, a paid-up, non-exclusive license and/or sublicense, as the case may be, of its rights in the Licensor Materials and Information and all intellectual property rights Controlled by Licensor related thereto that are not licensed to Licensee pursuant to the license in subsection (a) above, solely to the extent that the Licensor Materials and Information are necessary or useful to Licensees practice of the license granted in subsection (a) above.

Option to enter into Product License Agreement:
Licensor hereby grants to Japanese Licensee an exclusive option (an 'Option') to enter into a Product License Agreement with respect to those Permitted Antigens which have been designated as Product Antigens, as further described. Each calendar year during the term of this Agreement, Licensee may obtain up to Two (2) such Options with respect to Product Antigens, pursuant to the procedures set forth.

License Property
Licensed Technology shall mean the rights Controlled by Licensor in the Licensor Patent Rights and Licensor Know-How; provided, however, that the foregoing shall exclude the Excluded Technology.

Product shall mean (i) with regard to the Option Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to a Product Antigen or (b) Genetic Material encoding such an Antibody, wherein in respect of each Product, said Genetic Material does not encode multiple Antibodies; and (ii) with regard to a Product License Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to the Product Antigen (as defined in such Product License Agreement) or (b) Genetic Material encoding such an Antibody wherein, in respect of each Product, said Genetic Material does not encode multiple Antibodies.

Product Antigen shall mean (i) with regard to the Option Agreement, a Permitted Antigen as to which Licensee has obtained an Option, as further described in the Option Agreement; and (ii) with regard to a Product License Agreement, the Antigen described in the Product License Agreement.

Xenomouse Animals shall mean transgenic mice which are Controlled by Licensor and which contain unrearranged human immunoglobulin genes that are capable of producing human antibodies when immunized with an antigen.

XenoMouseâ„¢ is a leading technology for generating fully human antibody drugs useful in treating a wide range of diseases.

Field of Use
Field shall mean the use of Products (i) for human therapeutic, prophylactic and diagnostic medical purposes and as laboratory research reagen.

XenoMouseâ„¢ is a technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.

Research Field shall mean the immunization of XenoMouse Animals with Permitted Antigens, the use of materials derived or generated in whole or in part from such XenoMouse Animals that are so immunized, and the use of the XenoMouse Animals themselves, solely for the creation, identification, analysis, manufacture, research, and preclinical development of Products in the Field. For purposes of clarification, it is understood that 'immunization' of XenoMouse Animals with a Permitted Antigen includes the immunization of XenoMouse Animals with any formulation or construction of a Permitted Antigen, regardless of the three dimensional configuration of such Permitted Antigen, including, but not limited to, cell lines expressing such Permitted Antigen on their cell surface and chimeric molecules containing such Permitted Antigen; provided, however, that any research, development or use of Antibodies that bind to an excluded Antigen (other than to determine whether they bind to a Permitted Antigen) shall be outside of the scope of the licenses granted under the Option Agreement.

IPSCIO Record ID: 144995

License Grant
Licensor grants an exclusive license in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Know-How, to make, have made, use and sell Products in the Field.  During the research term, the Licensor shall not perform any research or development work in the field with any other party.
License Property
L6 Antibodies shall mean those certain Program Antibodies that are murine or chimeric antibodies and are specifically reactive immunologically with the L6 antigen, such L6 antigen having characteristics substantially  described, as amended, supplemented or modified from time to time.
Field of Use
The Field shall mean the in vivo diagnosis or treatment of solid tumors in humans through the use of one or more antibodies.

The Diagnostic Product shall mean a diagnostic product, containing one or more Program Antibodies, for use in the in vivo detection of solid tumors in humans.

The Therapeutic Product shall mean the final dosage formulation of a product incorporating pharmaceutical compositions containing a Program Antibody for use in the treatment of solid tumors in humans, regardless of the route of administration. Each different chemical formulation of a Therapeutic Product containing the same one or more Program Antibodies but no additional antibodies, except different formulations for use in the treatment of the same indication in the Field by different routes of administration, shall constitute a different Therapeutic Product.

IPSCIO Record ID: 280827

License Grant
The Parties are entering a research license and option agreement regarding the generation of human monoclonal antibodies to neurotactin, the Antigen, where the antibodies to the Antigen are generated through the use of certain Licensor technology.

Licensor shall transfer to Licensee the XenoMouse Animals and other materials.

The executed option will provide exclusivity.

License Property
Licensor Materials shall mean, collectively, the XenoMouse Animals and other materials specified and any XenoMouse Animals immunized with the Antigen.

The materials include Forty ( 40) XenoMouseâ„¢ animals;  2 mg human anti- KLH antibody (generated in XenoMouse);  Immunization protocol;  Fusion protocol;  and,  ELISA protocol for screening.

Field of Use
The Field of use is to develop antibody products for an undisclosed antigen in the field of inflammatory disease.
The research collaboration agreement is to generate fully human antibodies to an antigen target in the field of inflammation.

IPSCIO Record ID: 249076

License Grant
The Parties have entered into that certain Collaboration Agreement, with respect to a collaborative research and joint development and profit-sharing commercialization program between the Parties with respect to specified targets, antibodies and technology.

For the DCVax-Prostate Product,  Licensor grants an exclusive, worldwide, license, with a right to sublicense, to Licensee under the Designated Target IP that relates to PSMA, to research, develop, manufacture, have manufactured, use, sell, offer for sale, import and otherwise commercialize the DCVax-Prostate Product.

For the PSMA Related Diagnostic Products,  Licensor grants an exclusive, worldwide, irrevocable, perpetual, license, with a right to sublicense, to Licensee under the Designated Target IP that relates to, or is necessary to Exploit, Flt-4, to research, develop, manufacture, have manufactured, use, sell, offer for sale, import and otherwise commercialize Licensee Diagnostic Products for the in vitro or in vivo diagnosis of cancer, screening, monitoring, or selection of patients for specific treatment modalities, or for determining the dose of a therapeutic product the Licensee Flt-4 Diagnostic Field, each such Licensee Diagnostic Product, a Licensee Flt-4 Diagnostic Product, and Non-Antibody Products for the in vitro or in vivo diagnosis and treatment of cancer, and Licensor reserves for itself solely the right to research, develop, manufacture, have manufactured, use, sell, offer for sale, import or otherwise commercialize any Reserved Dovetailing Product provided, however, Licensor shall not promote Reserved Dovetailing Products for use in the Northwest Flt-4 Diagnostic Field, including providing written or other materials relating to use of the Reserved Dovetailing Products in the Licensee Flt-4 Diagnostic Field.

For the HuMAb® Licenses, Licensor grants the right to obtain from Licensor five (5) licenses under the HuMAb® Technology to develop, make, have made, use, sell, offer for sale and import on a worldwide basis selected antibody-based products directed against biological targets,  each a Licensee Target, on the terms set forth to this Agreement, used by Licensor in its standard cash-and-carry agreements.

License Property
Fucosyltransferase Fucosyl GM-1 shall mean the ganglioside fucosyl gm-1 FucGM-1.

Flt-4 shall mean the gene that is associated with Genbank Accession No, XP 003852 and allelic polymorphisms associated with such genes.

PSMA shall mean prostate specific membrane antigen related to the gene described in Genbank Accession No. NP 004467 and allelic polymorphisms associated with such gene.

CXCR-4 Product shall mean any antibody product, including any Antibody Product, with a therapeutically meaningful binding affinity for CXCR-4.

DCVax-Prostate Product shall mean that version of Licensors proprietary product that was in Phase III clinical trials under IND number BB IND 8602.

Designated Target shall mean each of PSMA , Fucosyl GM-1 or Flt-4 .

Field of Use
The field of use is Flt-4 Diagnostic Field and  PSMA Diagnostic Field.  The antibody products are for the diagnosis, prophylaxis or treatment of human diseases or conditions.

IPSCIO Record ID: 222550

License Grant
Licensee desires Licensor to conduct research with the Mice to generate fully human monoclonal antibodies to certain Antigens.

For the Evaluation License, Licensor grants an exclusive, nontransferable license for the term of the applicable Evaluation Period to use the Collaboration Technology relating to such Antigen solely for the purpose of evaluating whether Licensee shall desire to acquire a commercial license to such Product(s) directed against such Antigen.

For the Option for Commercial Licenses, Licensee shall have an option to obtain a commercial license with respect to Product(s) directed against such Antigen in the Field of Use in all countries of the Territory,

For the Commercial License,  Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensed Technology to make, have made, import, have imported, use, offer for sale and sell Product(s) directed against such Antigen in the Field of Use in the Territory.

For the Research License, Licensee shall have an irrevocable, perpetual, worldwide exclusive research license, without the right to sublicense, to make and use (but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Antibody{ies) and Antibody Cell(s) transferred by Licensor to Licensee, and any related Collaboration Technology, including Genetic Material(s) relating specifically and solely to such Antibody(ies) and Antibody Cell(s), in each case, and an irrevocable, perpetual, worldwide non-exclusive research license, without the right to sublicense, to make and use, but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Collaboration Technology relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, in each case, which is necessary for Licensee to make and use the same for research.

License Property
The patents relate to Transgenic non-human animals capable of producing heterologous antibodies.

The Collaboration Know How shall mean, with respect to each Antigen, any parts or derivatives of the Mice prepared by Licensor in connection with the applicable Immunization and delivered to Licensee, including without limitation, Antibody(ies), Antibody Cell(s), polypeptides, Genetic Material(s) or other biological materials derived directly or indirectly from the Mice delivered to Licensee, all information relating specifically and solely to the foregoing, including without limitation, technical data, protocols and methods and processes with respect to Product(s) directed against such Antigen and, all information relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, including without limitation, technical data, protocols and methods and processes.

Product(s) shall mean, with respect to an Antigen, a composition or compositions with each composition comprising one or more Antibody(ies), Antibody Cell(s) or Genetic Material(s).

Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.

HuMAb -Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies.  Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.

Bispecific antibodies, which enhance and direct the body's own immune system to fight disease; and immunotoxin  technology.

Field of Use
The Field of Use shall mean all uses of Product(s), including all human therapeutic, prophylactic and diagnostic uses of Product(s).

IPSCIO Record ID: 202852

License Grant
Licensor shall nominate the Antigen under a Master Research License and Option Agreement and obtain the right to obtain a Product License Agreement with respect to the Antigen for commercial use by Licensee.

For commercial license, Licensor shall grant an exclusive license or sublicense, as the case may be, with the right to grant sublicenses, under the Licensed Technology, to make and use Research Program Materials and Information solely to make and have made Product and to use, sell, lease, offer to sell or lease, import, export, otherwise transfer physical possession of or otherwise transfer title to Product, in the Territory for use in the Field.

License Property
The Antigen is known as properdin, as described in U.S. Patent Application No. 09/138,723 and PCT Application No. WO98/17500.

Licensor has rights in certain strains of transgenic mice, XenoMouse(TM) mice, that are capable of producing human antibodies when immunized with an antigen.

'PRODUCT' shall mean any dosage or formulation of a product comprising an Antibody which binds to the Antigen.

Field of Use
Licensee will use Licensor's XenoMouse(R) technology to generate fully human monoclonal antibodies to the complement protein properdin. These human monoclonal antibodies are being designed for use in the fields of cardiovascular and inflammatory diseases.

IPSCIO Record ID: 28073

License Grant
The Canadian University hereby grants to the Canadian Licensee an exclusive world-wide license, in respect of the Type I Technology and a non-exclusive world-wide license in respect of the Type II Technology, to make use of, or caused to be used, sell and/or sublicense the Technology and any know how associated therewith or which forms a basis thereof whether it is the Scientist's know how, and to manufacture, commercialize, distribute, market, import, export, offer to sell, sell, lease and/or license or sublicense Products on the terms and conditions hereinafter set forth (the License).
License Property
The Scientist of  the University has been engaged in research during the course of which he has developed certain recombinant viral antigens, murine antibody clones and an animal model.

Type I Technology shall mean the recombinant viral antigens and murine antibody clones and Type II Technology shall mean the animal model.

1. Antigens cloned, expressed and purified in the Tyrrell University laboratory as follows:

·
Human Hepatitis B(HBV) Core Antigen (short)

·
Duck Hepatitis B(DHBV) Surface Antigen

·
Duck Hepatitis B(DHBV) Polymerase Protein

·
Duck Hepatitis B(DHBV) Core Protein

2. Murine antibody clones developed in the Tyrrell University laboratory as follows:

·
Monoclonal Antibody 1D12 to HBV core antigen

·
Monoclonal antibodies 2C12, 2D12, 2C11, 2A12, 4A10, 1F9, 2G11 to HBV surface antigen

·
Monoclonal Antibody 3A8, 2C4 to HBV Polymerase

·
Monoclonal Antibody 1F4 to DHBV Surface Antigen

·
Monoclonal Antibodies 9A8, 8D6, 7G4, 7G5, 7G10, 9F2, 9G8, 1A9, 4A9, 1H5 to DHBV Core Antigen.

3. Animal model as follows:

·
Hepatitis B Duck Model

Including any replications of progeny of the above made by the Licensee and, if that which is made by the Licensee, constitutes cells or DNA molecules. Type II Technology includes all modifications, improvements and variants thereof and any data or information in relating thereto including sequence information.

Field of Use
Licensee will be commercializing novel therapeutic approaches to treat diseases, excluding cancer, in humans created by identifiable microbial pathogens.

IPSCIO Record ID: 266837

License Grant
For the Research License Grants, Licensor shall automatically be deemed to have granted to Licensee a non-exclusive, worldwide license under the Licensor Technology solely to conduct the Research Program.

For the Exclusive License Grants, with respect to the First Exclusive Antigen, and the Option Exercise Fee  with respect to the Second Exclusive Antigen, and commencing as of the date Licensor has received the ADC Access Fee or Option Exercise Fee, as the case may be, from Licensee, Licensor shall automatically be deemed to have granted to Licensee an exclusive, even as to Licensor, license under the Licensor Technology, with the right to sublicense to discover, develop, have developed, make, have made, import, use, offer for sale, and sell Licensed Products that bind specifically to the Exclusive Antigen within the Field in the Territory.

For the Grant of Option, Licensor hereby grants Licensee an option to obtain the Exclusive License of this Agreement to the Second Exclusive Antigen during the Option Period.

For the Replacement Right; Dropped Antigen,  Licensee shall have the right to designate the first exclusive antigen as a Dropped Antigen for purposes of this Agreement by providing Licensor with written notice of same.  Licensee shall have the right to designate one (1) additional Designated Antigen as a replacement for the Dropped Antigen in accordance with  the procedure.

License Property
The patents relate to tumor inhibitors.

The patent applications include Pentapeptide Compounds and uses related thereto; Drug Conjugates and their uses for Treating Cancer, an Autoimmune Disease or an Infectious Disease; and, Monomethylvaline Compound Capable of Conjugation to Ligands.

ADC technology can be widely employed to increase the therapeutic potential of monoclonal antibodies through stable attachment to cell-killing drug payloads.

Field of Use
Field means the treatment and diagnosis of conditions and diseases in humans and animals; provided that with respect to the use of the BMS Technology the Field shall be limited to monoclonal antibody targeting applications.

The proprietary ADC technology for use with Licensee's proprietary antibodies for the treatment of cancer.

IPSCIO Record ID: 121121

License Grant
The purpose of this agreement is to establish a research collaboration to apply such Licensors technology and expertise to the identification and characterization of targets that mediate the effect of test compounds in model organisms, and to provide for the development and commercialization, based on such research, of novel prophylactic, therapeutic and diagnostic products or new indications or expanded labeling for existing products.

The parties desire to establish a technology sharing program that relates to its high throughput lead optimization technology, and Licensor will transfer to Licensee its proprietary technology that relates to genetics and molecular biology in C. elegans and Drosophila.

Licensor grants a limited, non-exclusive, non-transferable, worldwide, perpetual license to use and practice the Licensors Core Technology, Core Technology Patents, and any Improvement Inventions made solely by Licensor to the Licensees Core Technology solely for its own internal research and discovery efforts in the Field.

Licensor grants a limited, non-exclusive, non-transferable, world-wide, perpetual license to use, adapt, reproduce, modify, localize, and create derivative works of the FlyTag Database, provided that all such uses of the FlyTag Database are solely for Licensees internal or collaborative research purposes, are used in the same manner, and subject to the same terms and conditions, as apply to the FlyTag Database Research Results.

For Research Results, Licensor grants an exclusive, worldwide, royalty-bearing license to use Research Results pertaining to Selected Targets, Product Targets, Mammalian Targets and Pursued Disclosed Targets for research and drug discovery and development in the Field, and to research, develop, import, use, sell, offer for sell, and commercialize Collaboration Compounds, Licensed Products and New Indications in the Field.

For Target Patents, Licensor grants a non-exclusive, worldwide, royalty-bearing license under any Patents that are Controlled by Licensor or its Affiliates and claim any of the Research Results and/or any Selected Targets, Pursued Disclosed Targets or Mammalian Targets, solely to discover, research and develop Collaboration Compounds, Licensed Products, and New Indications in the Field, and to research, develop, import, use, sell, offer for sell, and commercialize Licensed Products and New Indications in the Field.

For Novel Target Patents, Licensor grants an exclusive, worldwide, royalty-bearing license under any and all Novel Target Patents that, but for the license granted hereunder, would be infringed by the manufacture, use or sale of Gene Products and other Biotherapeutics, solely to discover, research, develop, import, use, sell, offer for sell, and commercialize Gene Products and Biotherapeutic Products.

License Property
Licensor is a biotechnology company that has expertise and proprietary technology relating to genetic model systems, genomics and computational biology and is applying such technology to discover and validate targets for drug discovery in a variety of disease areas.

A Novel Target means a mammalian orthologue of a Selected Target, which orthologue was identified by or on behalf of Licensor pursuant to work conducted under the Mode of Action Program.

An Unlinked Related Target means a Related Target that, at the time of identification of such target by Licensee or Licensor, is not Known to be a target for drug discovery.

A Biotherapeutic Product means any therapeutic or prophylactic product for treatment or prevention of diseases or conditions in humans that comprises or incorporates an antibody against a Mammalian Target, or an antisense compound based upon a Mammalian Target sequence, or a gene therapy product based upon the sequence of a Mammalian Target.

A Diagnostic Product means a product that facilitates identification of patients having a particular disease or having a predisposition to a particular disease, and/or monitors the prognosis or progression of a disease in a patient, by the detection of either sequence differences in different alleles of a Mammalian Target, or the presence or absence of a certain Mammalian Target, or the presence or absence of the protein product of a certain Mammalian Target.

A Gene Product means any therapeutic or prophylactic product for treatment of humans that comprises or incorporates the gene product of a Mammalian Target or a mutein or fusion protein based thereon.

A Pharmacogenomic Product means a product that is primarily used to select between two or more therapeutic or prophylactic regimens for a human, wherein at least one such therapeutic or prophylactic regimen involves a compound that could be used to treat and/or prevent a disease, and where the selected regimen is judged based on the use of the pharmacogenomic product to be of most likely benefit and/or to do the least harm to a patient, and provided that such selection is made based on the genotype of such human at certain genetic loci (including by detection of certain protein products indicative of the necessary genotype) as determined by use of such product to detect either sequence differences in different alleles of a Mammalian Target, or the presence or absence of a certain Mammalian Target, or the presence or absence of the protein product of a certain Mammalian Target.

The FlyTag Database means the sequence data within the database maintained by Licensor under the name FlyTag as of the Effective Date in the form previously released by Licensor to a contractual partner

Field of Use
The Field is the treatment, prophylaxis and diagnosis of disease in humans.  Licensee is a multinational health care company that has expertise and capability in developing and marketing human pharmaceuticals and has research and development programs in the area of medicinal chemistry.

IPSCIO Record ID: 227247

License Grant
Subject to Third Party rights the United Kingdom Licensor, government organization, grants to the United Kingdom Licensee during the continuance of this Agreement the following rights and licenses under the Patent Rights and the Technology on the following conditions:
For the Exclusive Rights:
Licensor grants the exclusive right and license under Licensee License Conditions to identify, develop, make, have made, import, market and sell selective antibodies for human in vivo use and includes using an antibody gene as a therapeutic entity in gene therapy provided always that Licensee will grant up to six exclusive sub-licenses to develop, make, have made, use, import, market and sell a specific antibody product directed at a particular antigen, for the avoidance of doubt it is declared antibodies derived from  SCID Hu mice would count within this total, to the Collaborative Centre, but excluding any right of access or license to use Licensee Libraries, with the right for the Collaborative Centre to sub-sub license for royalties payable by the Collaborative Centre to Licensee and on financial terms.

And, the exclusive right and license under Licensee License Conditions to use antibodies as part of a medical, but not a research, procedure involving in vitro selection of Rare Cell Population for therapy or diagnosis.

And, the exclusive right and license under Licensee License Conditions to provide Antibody Isolation Services for third parties.

And, the exclusive right and license under Licensee License Conditions to use and exploit commercially in any way whatsoever the inventions the subject of the patent and its corresponding patents for Diabodies except in the following fields of use:
(a) biosensors;
(b) therapeutic products which include mammalian retroviruses encoding diabodies as a fusion with viral coat proteins; and
(c) diabodies generated from combinations of four specific antibodies.

And, the exclusive right and license under Licensee License Conditions to use molecules isolated by the Technology for use in the manufacturing process of pharmaceutical products or intermediates.

And, the exclusive right and license under Licensee License Conditions to develop, make, have made, use, import, market and sell Catalytic Antibodies or Research Products.

And, for Co-exclusive rights:
the co-exclusive right and license for Licensee under Licensee License Conditions to improve. develop, make, have made, import, market and sell antibodies originally isolated by hybridoma derived methods from non-primate sources which have been humanized using CDR grafting techniques the subject of the patent known as Winter l, derived from the UK Patent application UK 860 7679 filed 27 March 1986-and US Parent Application 903776.

And, the co-exclusive right and license for Licensee under Licensee License Conditions to use antibody structural information to design non-antibody drug candidates.

And, for Gene-sequencing and analysis rights,  the exclusive right and license under Licensee License Conditions to use antibody repertoires and libraries and antibodies isolated from them in the identification, analysis and validation of targets for therapeutic, diagnostic or prophylactic entities arising from gene sequencing data and analysis provided always that Licensor shall have the right, which for the avoidance of doubt it is declared and agreed does not include any right of access to or license to use the Licensee Libraries, to grant collaborative licenses.

And, for the Third Party License, a non-exclusive license to third party companies who are licensed by Licensor to use and exploit other Licensor pending or granted patent rights or technology which third
parties focus and which other Licensor rights are not principally in the field of therapeutic antibodies.

And, for the non-exclusive rights,  the non exclusive right and license under Licensee License Conditions for all purposes other than those specifically excluded.

This Party agreement is, in relation to such a target, an exclusive license to develop, make, have made, market and sell only therapeutic antibodies to any such target; and, in relation to such a Product which is an actual or potential therapeutic antibody an exclusive license to develop, make, have made, market and sell only such therapeutic antibody.

License Property
Products means any product or formulation whose development, manufacture, use or sale would, absent a license, infringe the Patent Rights or utilize the Technology.

Catalytic Antibodies means antibodies which bind to and catalyze the chemical transformation of a substrate and in which an antibody binding region is involved in said catalysis.

Patents include: Cloning Immunoglobulin Variable Domain Sequences; Methods for producing members of specific binding pairs; Production of chimaeric antibodies, a combinational approach; Production of anti-self antibodies from antibody segment repertoires and displayed on phage; Methods for producing members of specific binding pairs; SBP members with a chemical moiety covalently bound within the binding site production and selection thereof; Recombinant Binding Proteins and Peptides; and, Treatment of cell populations.

Field of Use
The use of the antibodies is intended for medical procedure, not research.  

The third party rights are for the field of human drug therapy by antibodies directed against the CD4-binding domain of the HIV-1 gp 120 protein.

IPSCIO Record ID: 248094

License Grant
The Parties are collaborating in the validation of targets for, and the discovery, development and commercialization of small molecules, antibodies, antisense molecules, proteins and other therapeutic agents, and diagnostic products.

For the Research Licenses, Licensor grants a worldwide, co-exclusive license during the Research Program Term, under Licensors rights to the Program Intellectual Property, to validate Program Targets for the identification, evaluation and optimization of Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules for use as Small Molecule Drugs or Biotherapeutic Products, as the case may be, in the Metabolic Disease Field, and, identify, evaluate and optimize Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules through the use of such Program Targets for use as Small Molecule Drugs or Biotherapeutic Products. as the case may be, in the Metabolic Disease Field, and, undertake Candidate Characterization of Program Compounds and Program Biotherapeutics in the conduct of the Research Program, and, undertake such other activities as may be necessary in furtherance of the Research Program.

Licensor grants a worldwide, non-exclusive license, under Licensors rights to the Program Intellectual Property, to validate Licensee Unilateral Targets for the identification, evaluation and optimization of Small Molecules. Antibodies, Antisense Molecules, Proteins and/or Other Molecules for use as Small Molecule Drugs or Biotherapeutic Products, as the case may be, in the Metabolic Disease Field, and, identify, evaluate and optimize Small Molecules, Antibodies. Antisense Molecules, Proteins and/or Other Molecules, including those that constitute the Associated Chemistry or the Associated Biotherapeutics, if any, of a Program Target that becomes a Licensee Unilateral Target, through the use of such Millennium Unilateral Targets for use as Small Molecule Drugs or Biotherapeutic Products. as the case may be, in the Metabolic Disease Field, and,  undertake Candidate Characterization of such Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules.

Licensor grants a worldwide, non-exclusive license, under Licensors rights to the Program Intellectual Property, to use the Licensor Released Compounds for internal research purposes only.

Licensor grants a worldwide, co-exclusive license, under Licensors rights to the Program Intellectual Property, to Develop and Manufacture Joint Drug Development Candidates or DDCs for use as Joint Products; and, make, have made, use, sell, offer for sale, import and export Joint Products in the Territory; and, undertake such other activities as may be necessary in furtherance of the Development Program and the Commercialization Program.

Licensor grants a worldwide, non-exclusive license, under Licensors rights to the Program Intellectual Property, to Develop and Manufacture Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules, as the case may be, identified through the use of Licensee Unilateral Targets for use as Licensee Unilateral Products, and, a worldwide, exclusive license, under Licensors rights to the Program Intellectual Property, to Develop and Manufacture Small Molecules included in a Licensee Unilateral Targets Associated Chemistry, and, Antibodies, Antisense Molecules, Proteins and/or Other Molecules included in a Licensee Unilateral Targets Associated Biotherapeutics, and, Licensee Unilateral DDCs, in each case, for use as Licensee Unilateral Products: and, a worldwide, exclusive, license, under Licensors rights to the Program Intellectual Property, to make. have made, use, sell, offer for sale, import and export Licensee Unilateral Products in the Territory,

Licensor grants a worldwide, co-exclusive license, under Abbotts rights to the Program Intellectual Property, to develop, make, have made, use, sell, offer for sale, import and export Third Party Program Diagnostics for use in the Metabolic Disease Field in the Territory, and, to develop Joint Program Diagnostics for use in the Metabolic Disease Field in the Territory. Such license shall carry an obligation of profit-sharing with respect to Third Party Program Diagnostics sold in the Territory.

Licensor grants a worldwide license, under Licensors rights to the Program Intellectual Property, to develop, make, have made, use, sell, offer for sale, import and export Licensee Unilateral Diagnostics for use in the Metabolic Disease Field in the Territory.

License Property
Program Target means any Druggable Target or Biotherapeutic Gene for which the Joint Research Committee determines that there exists reasonable scientific rationale for the utility of such target or gene for the identification of Small Molecules, Antibodies, Antisense Molecules, Proteins or Other Molecules intended for use as Small Molecule Drugs or Biotherapeutic Products, as the case may be, in the Metabolic Disease Field.

Antisense Molecule means a nucleic acid or a functional analog, derivative or homologue thereof which is complementary to a segment of DNA of a target gene or such target genes cognate RNA and which, upon delivery by any means, alters the transcription, processing, elaboration, RNA expression or protein production of or by such target gene.

Associated Biotherapeutics means, with respect to a Program Target that has been designated a Unilateral Target or a Released Target, as the case may be, all Program Biotherapeutics that interact with such target or are encoded by such target or are chemically modified versions of the Program Biotherapeutics encoded by such target.

Biotherapeutic Product means a Therapeutic Antibody Product, a Therapeutic Antisense Product, a Therapeutic Protein Product, and/or a Therapeutic Other Molecular Product, as the case may be.

Field of Use
The use is to aid in the diagnosis, prognosis, monitoring, prevention and treatment of certain metabolic diseases.  Metabolic Disease Field means Obesity, Type 1 Diabetes and Type 2 Diabetes. The Metabolic Disease Field specifically excludes insulin therapy and autoimmune and immunomodulating mechanisms for Type 1 Diabetes.

IPSCIO Record ID: 245920

License Grant
Licensor grants an exclusive license in the Territory under the Licensor Technology solely for the purpose of conducting research and development activities on the Research Antigens and evaluating EOSs interest to exercise the Options.

Licensor grants an exclusive Option for each Research Antigen designated to obtain the Exclusive License set forth during the Option Period.

If Licensee elects to exercise its option to acquire an Exclusive License with respect to a particular Research Antigen, and Licensee pays the Option Exercise Fee, then subject to the terms and conditions of this Agreement, and commencing as of the date that Licensor has received the Option Exercise Fee from Licensee, Licensor is automatically deemed to grant, and in such event hereby grants, to Licensee, on a Research Antigen-by-Research Antigen basis, a worldwide, exclusive, even as to Licensor, nontransferable, royalty-bearing license under the Licensor Technology, with the right to sublicense, to discover, have discovered, to develop, have developed, make, have made, import, have imported, export, have exported, use, sell and have sold Products directed toward such Research Antigen within the Field in the Territory.

License Property
Licensor owns or controls intellectual property rights relating to certain drug conjugation and linker technology.

The licensors patents and technology are for Antibodies, Research Antigens, Exclusive Antigens, and Jointly-Invented Inventions Related thereto.

Antigen means any protein, including any glyco- or lipo-protein, carbohydrate, compound or other composition, and any fragment, peptide or epitope thereof, to which an antibody hinds.

Product means any and all products where the manufacture, sale or use of such products would have constituted a misappropriation of Drug Conjugation Technology, Licensor Know-How, Improvements or New Technologies, and/or an infringement of the Licensed Patents but for the licenses granted in this Agreement.

The binding of an antibody to the surface of a cancer cell rarely induces cell death by itself.  Enhancing the potency of antibodies through the linkage of drug payloads provides a means to selectively kill cancer cells while limiting damage to normal tissue.

Field of Use
The Parties will collaborate to use Licensor's toxic payload technology with Licensee's proprietary monoclonal antibodies directed against novel cancer targets derived from their analyses of the human genome.

IPSCIO Record ID: 237232

License Grant
With this amendment, in the event Licensor of the United Kingdom notifies Licensee that a Product License can be granted to Licensee with respect to Products against a Nominated Target, then upon receipt by Licensor of the applicable Acceptance Fee, Licensor agrees to grant and hereby grants to Licensee and its Affiliates a non-exclusive, royalty-bearing license, with the right to sublicense, under the Antibody Phage Display Patents and Licensor Know-How to Exploit Products against such Nominated Target in the Territory.
License Property
The Antibody Phage Display Patents include Single Domain Ligands, Receptors Comprising said Ligands, Methods for their Production and Use of Said Ligands and Receptors, and, Co-expression of Heteromeric Receptors, and, Method for Isolating Receptors Having a Preselected Specificity, and, A new method for tapping the immunological repertoire, and, Methods for producing members of specific binding pairs, and, Treatment of Cell Populations, and, Production of chimeric antibodies – a combinational approach, and, Production of anti-self antibodies from antibody segment repertoires and displayed on phage, and, Methods for producing members of specific binding pairs, and, SBP members with a chemical moiety covalently bound within the binding site; production and selection thereof, and, Recombinant Binding Proteins and peptides,and, Labelling and selection of Specified Binding Molecules.

The Licensor Know-how includes Licensor Training Manual Antibody Phage Display 2002, and, Licensor mammalian expression IgG vectors:
pEUl.2 (human gamma-I heavy chain)
pEU3.2 (human kappa light chain)
pEU4.2 (human lambda light chain)
pEU8.2 (human gamma-4 heavy chain)

Field of Use
The agreement is for nominated target(s) which is(are) potentially useful for the development of any Diagnostic Antibody Product and/or any Therapeutic Antibody Product.

Diagnostic Antibody Product means any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction or disease management of a disorder for any indication outside the Excluded Field which contains, comprises or the process of development or manufacture of which utilizes a Licensor Licensable Antibody.  The term Diagnostic Antibody Product shall not include any Research Product.

Therapeutic Antibody Product means any preparation for the treatment or prevention of disease, infection or other condition in humans for any indication outside the Excluded Field which contains, comprises, or the process of development or manufacture of which utilizes, a Licensor Licensable Antibody. The term Therapeutic Antibody Product shall not include any Research Product.

Excluded Field means the discovery, isolation, characterization, research, development, and/or commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific rationale or activity is neuronal and/or glial mechanisms of action or neuroprotection:
(a) neurodegenerative conditions, including but not limited to (i) Alzheimers disease, and (ii) Parkinsons disease, but in both instances, excluding the  treatment and/or prevention of neurodegenerative conditions in humans associated with P-amyloid deposition (including, without limitation, Alzheimers disease and/or Mild Cognitive Impairment, using either (A) immunological approaches directed at one or more epitopes of AP or any naturally occurring variants thereof, including, without limitation, the administration of an Antibody, or (B) use of a beta secretase inhibitor, including, without limitation, the administration of an Antibody);
(b) diabetic neuropathy;
(c) pain, including, but not limited to, (i) post-operative pain, (ii) chronic pain and (iii) neuropathic pain,
(d) spinal cord injury;
(e) multiple sclerosis; and/or
(f) stroke, as a disease of the cerebrovasculature.

The term Excluded Field shall not include the diagnosis, treatment and/or prevention of the above disease conditions caused by infectious pathogenic micro-organisms.

IPSCIO Record ID: 274922

License Grant
The Parties agreed to amend and restate several sections of the original agreement to include but not limited to the following:

Licensor hereby grants non-exclusive licenses (other than the Co-exclusive License for Therapeutic Immunization for HPV Antigens granted in this Agreement C below) in accordance with the terms stated herein.

In consideration of the obligations assumed by Licensee hereunder, Licensor hereby grants to Licensee and to any affiliates of Licensee the following licenses without the right to sublicense as set forth in this paragraph under technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the territory and in the field all products and/or compinations, subject to the following:

(A1) For prophylactic immunization within the field, Licensor grants a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens
HBV Antigens
Influenza Antigens
Chlamydia Antigens
Mycobacterium Antigens
RSV Antigens
Malaria Antigens
Steptococcus pneumonia Antigens

(A2) For prophylactic immunization within the field, Licensor grants to Licensee a non-exclusive license for the following licensed antigens and no other antigens.

HIV Antigens

(B) For therapeutic immunization within the field, Licensor grants Licensee a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HBV Antigens
Chlamydia Antigens
Mycobacterium Antigens

(C) For therapeutic immunization within the field, licensor grants Licensee a co-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens

The regulatory and development milestone payments and the patent royalties for each Licensed Antigen in the non-exclusive licenses granted in (A1) and (B) shall be reduced by a certain percent.

License Property
The Products are for therapeutic immunization relating to infectious diseases that such as:

HBV  – hepatitis B virus
HPV – human papillomavirus
HIV – human immunodeficiency virus

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 240620

License Grant
The Parties are collaborating in the validation of targets for, and the discovery, development and commercialization of small molecules, antibodies, antisense molecules, proteins and other therapeutic agents, and diagnostic products.

For the Research Licenses,  Licensor grants a worldwide, co-exclusive, non-royalty-bearing license during the Research Program Term, under Licensors rights to the Program Intellectual Property, to validate Program Targets for the identification. evaluation and optimization of Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules for use as Small Molecule Drugs or Biotherapeutic Products, as the case may be, in the Metabolic Disease Field, and, identify, evaluate and optimize Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules through the use of such Program Targets for use as Small Molecule Drugs or Biotherapeutic Products, as the case may be, in the Metabolic Disease Field, and, undertake Candidate Characterization of Program Compounds and Program Biotherapeutics in the conduct of the Research Program, and, undertake such other activities as may be necessary in furtherance of the Research Program.

Licensor grants a worldwide, non-exclusive license, under Licensors rights to the Program Intellectual Property, to validate Abbott Unilateral Targets for the identification, evaluation and optimization of Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules for use as Small Molecule Drugs or Biotherapeutic Products. as the case may be. in the Metabolic Disease Field, and, identify. evaluate and optimize Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules, including those that constitute the Associated Chemistry or the Associated Biotherapeutics, if any, of a Program Target that becomes an Licensee Unilateral Target, through the use of such Licensee Unilateral Targets for use as Small Molecule Drugs or Biotherapeutic Products, as the case may be, in the Metabolic Disease Field, and,
undertake Candidate Characterization of such Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules.

Licensor grants a worldwide, non-exclusive, license, under Licensors rights to the Program Intellectual Property, to use the Licensor Released Compounds for internal research purposes only.

For the Development and Commercialization Licenses,  Licensor grants a worldwide, co-exclusive license, under Licensors rights to the Program Intellectual Property, to Develop and Manufacture Joint Drug Development Candidates or DDCs for use as Joint Products; and, make, have made, use, sell, offer for sale, import and export Joint Products in the Territory; and, undertake such other activities as may be necessary in furtherance of the Development Program and the Commercialization Program.

Licensor grants a worldwide, non-exclusive license, under Licensors rights to the Program Intellectual Property, to Develop and Manufacture Small Molecules, Antibodies, Antisense Molecules, Proteins and/or Other Molecules, as the case may be, identified through the use of Licensee Unilateral Targets for use as Licensee Unilateral Products (ii) a worldwide, exclusive,  license, under Licensors rights to the Program Intellectual Property, to Develop and Manufacture Small Molecules included in a Licensee Unilateral Targets Associated Chemistry, and, Antibodies, Antisense Molecules, Proteins and/or Other Molecules included in an Licensee Unilateral Targets Associated Biotherapeutics, and, Licensee Unilateral DDCs, in each case, for use as Licensee Unilateral Products, and, a worldwide, exclusive, license, under Licensors rights to Program Intellectual Property, to make, have made, use, sell, offer for sale, import and export Licensee Unilateral Products in the Territory.

Licensor grants a worldwide, co-exclusive license, under Licensors rights to the Program
Intellectual Property, to develop, make, have made, use, sell, offer for sale, import and export Third Party Program Diagnostics for use in the Metabolic Disease Field in the Territory, and, a worldwide, co-exclusive license, under Licensors rights to the Program Intellectual Property, to develop Joint Program Diagnostics for use in the Metabolic Disease Field in the Territory and, a worldwide, exclusive license, under Licensors rights to the Program Intellectual Property, to make, have made, use, sell, offer for sale, import and export Joint Program Diagnostics for use in the Metabolic Disease Field in the Territory.

Licensor grants a worldwide license, under Licensors rights to the Program Intellectual Property, to develop, make, have made, use, sell, offer for sale, import and export Licensee Unilateral Diagnostics for use in the Metabolic Disease Field in the Territory.

Licensor grants a worldwide, co-exclusive license, under Licensors rights to the Program Intellectual Property, to use Released Targets to develop Diagnostics for use in the Metabolic Disease Field, and, a worldwide, exclusive license, under Licensors rights to the Program Intellectual Property, to make, have made, use, sell, offer for sale, import and export Licensee Released Diagnostics for use in the Metabolic Disease Field in the Territory.

License Property
Program Target means any Druggable Target or Biotherapeutic Gene for which the Joint Research Committee determines that there exists reasonable scientific rationale for the utility of such target or gene for the identification of Small Molecules, Antibodies, Antisense Molecules, Proteins or Other Molecules intended for use as Small Molecule Drugs or Biotherapeutic Products, as the case may be, in the Metabolic Disease Field.

Antisense Molecule means a nucleic acid or a functional analog, derivative or homologue thereof which is complementary to a segment of DNA of a target gene or such target genes cognate RNA and which, upon delivery by any means, alters the transcription, processing, elaboration, RNA expression or protein production of or by such target gene.

Associated Biotherapeutics means, with respect to a Program Target that has been designated a Unilateral Target or a Released Target, as the case may be, all Program Biotherapeutics that interact with such target or are encoded by such target or are chemically modified versions of the Program Biotherapeutics encoded by such target.

Biotherapeutic Product means a Therapeutic Antibody Product, a Therapeutic Antisense Product, a Therapeutic Protein Product, and/or a Therapeutic Other Molecular Product, as the case may be.

Field of Use
The use is to aid in the diagnosis, prognosis, monitoring, prevention and treatment of certain metabolic diseases.  Metabolic Disease Field means Obesity, Type 1 Diabetes and Type 2 Diabetes. The Metabolic Disease Field specifically excludes insulin therapy and autoimmune and immunomodulating mechanisms for Type 1 Diabetes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.